PharmaMax is a innovation powerhouse within the Chinese pharmaceutical and consumer healthcare industry. PharmaMax is dedicated to improving the health and quality of life of China’s residents through highly innovative, world class quality products to treat chronic conditions. Its international management team have developed and commercialized over 250 new products for the global marketplace.
PharmaMax, founded in 2009 is based in Taizhou City, Jiangsu Province and New Jersey, USA. The privately held company is a China-American joint venture between Jiangsu Changtai LTD and PharmaMax USA. This structure provides the perfect blend of international quality, scientific standards and governance with the ability to execute flawlessly within the complex regulatory environment of China.
The PharmaMax portfolio is focused on high value prescription and consumer healthcare products which treat chronic conditions. In addition, PharmaMax strategically partners with a number of international companies from the US and EU to bring breakthorough products to the massive China marketplace.
For other customers, it offers turn-key "concept to commercialization" capabilities and services.
The PharmaMax facilities are strategically located in Taizhou City and within the Chinese Medical City (CMC). Our current facility is 3,000 square meters of floor space for R&D, cGMP Manufacturing and Office Adminstration. PharmaMax is expanding operations to a new 16,000 square meter cGMP facility and company headquarters in early 2015.
PharmaMax and its strategic partners benefit from a number of special privileges intended to facilitate and expedite registrations and approvals as well as support to protect against IP infringement in China.
